Q2 FY2026 EarningsQ2 FY2026 results significantly exceeded consensus expectations across all major financial metrics. Revenue reached $19.9M, a 53.8% beat against the $12.9M estimate, driven by robust Elfabrio® sales. The company achieved a GAAP net income of $3.8M ($0.05 per share) compared to a forecasted net loss of $1.0M (-$0.01 per share). Full-year FY2026 revenue guidance was reaffirmed at $78M–$83M, which remains consistent with current market scaling expectations for its rare disease portfolio.
Financial report interval: 2026.03.30 - 2026.06.30
Overview: Protalix Biotherap(PLX) the Revenue is 19.9 M (+27.07%), Beat estimate;the EBIT is 4.672 M (+298.6%), Beat estimate;the EPS is 0.05 (--%), Beat estimate.
Actual
YoY
Estimate
YoY
Vs estimate
YoY
RevenueExceed expectations
0.02B27.07%
0.01B17.41%
+0.01B44.48%
EBITExceed expectations
0.00B298.63%
-0.00B212.46%
+0.01B511.09%
EPSExceed expectations
0.05--
-0.01--
+0.0600--%
Revenue
ActualEstimateUnit: USD
qf
EBIT
ActualEstimateUnit: USD
qf
Net income
ActualEstimateUnit: USD
qf
EPS
ActualEstimateUnit: USD
qf